PHILADELPHIA – A University of Pennsylvania team has completed the first successful demonstration of a noninvasive optical device to monitor cerebral blood flow in patients with acute stroke, a leading cause of disability and death.
The ultimate goal of this research is to improve the management of patients with stroke and other brain disorders by providing continuous bedside monitoring of brain blood flow and metabolism.
“Our preliminary study demonstrates that blood flow changes can be reliably detected from stroke patients and also suggests that blood flow responses vary significantly from patient to patient,” lead author Turgut Durduran said.
Ischemic stroke is the leading cause of morbidity and long-term disability in the United States, with projected cost of stroke care estimated at trillions of dollars during the next five decades. Stroke accounts for nearly 10 percent of deaths in the western hemisphere and about 5 percent of health-care costs.
The device being developed uses embedded optical probes that are placed over major cortical blood vessels in each hemisphere of the brain. The technology, diffuse correlation spectroscopy is a non-invasive system that uses lasers, photon-counting detectors, radio-frequency electronics, data processors and a computer monitor to display user-friendly images of functional information to physicians and nurses.
“What we have demonstrated is a working prototype of a non-invasive brain probe that uses diffusing light to detect physiological changes such as blood flow, blood-oxygen saturation and hemoglobin concentration to inform clinicians about their treatments,” Arjun Yodh, professor of physics in the School of Arts and Sciences at Penn and principal investigator of the study, said.
The study is part of a $2.8 million, five-year Bioengineering Research Partnership grant from the National Institutes of Health and the University of Pennsylvania Health System Comprehensive Neuroscience Center. BRP grants are awarded to interdisciplinary teams that combine basic, applied and translational research for important biological or medical problems. Yodh is joined by Rick Van Berg from the High Energy group of the Department of Physics in the School of Arts and Sciences and clinical collaborators John Detre, MD, Associate Professor of Neurology and Radiology, Joel Greenberg, PhD, Research Professor of Neurology and Scott Kasner, MD, MSCE, Associate Professor of Neurology in the School of Medicine at Penn..
“Stroke is caused by a reduction in blood flow to the brain, yet brain blood flow is rarely if ever measured in stroke patients because most existing methods to measure blood flow require costly instrumentation that is not portable,” Detre said. “The ability to quantify tissue hemodynamics at the bedside would provide new opportunities both to learn more about blood-flow changes in patients with acute stroke and to optimize interventions to increase blood flow for individual patients, potentially even allowing these interventions to be administered before the onset of new neurological symptoms.”
###
PENN Medicine is a $3.6 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #4 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,700 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System (UPHS) includes its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s top ten “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center. In addition UPHS includes a primary-care provider network; a faculty practice plan; home care, hospice, and nursing home; three multispecialty satellite facilities; as well as the Penn Medicine Rittenhouse campus, which offers comprehensive inpatient rehabilitation facilities and outpatient services in multiple specialties.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.